4th Quarter - Report

MEHLMAN CONSULTING, INC. for AARP, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Part D Beneficiary out of pocket and cost sharing protections. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1865 - Further Consolidated Appropriations Act, 2020

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (116th), S. 2543 (116th), H.R. 1865 (116th)

Pharmacy PHA

S.1895 - Lower Health Care Costs Act including issues relating to drug pricing included in S. 340 and H.R. 965 - The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S. 2543 - Prescription Drug Pricing Reduction Act of 2019. House prescription drug price transparency legislation.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 965 (116th), S. 340 (116th), S. 1895 (116th), S. 2543 (116th)

Taxation/Internal Revenue Code TAX

Medical expense deduction

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.